CN1075081A - The compound method of colloid anaesthetic compound - Google Patents

The compound method of colloid anaesthetic compound Download PDF

Info

Publication number
CN1075081A
CN1075081A CN 92100755 CN92100755A CN1075081A CN 1075081 A CN1075081 A CN 1075081A CN 92100755 CN92100755 CN 92100755 CN 92100755 A CN92100755 A CN 92100755A CN 1075081 A CN1075081 A CN 1075081A
Authority
CN
China
Prior art keywords
compound
anaesthetic
colloid
carmellose
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 92100755
Other languages
Chinese (zh)
Inventor
刘合年
任渝江
姜洪贵
熊兴中
陈晓敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
No44 Hospital Land Force For Pla
Original Assignee
No44 Hospital Land Force For Pla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by No44 Hospital Land Force For Pla filed Critical No44 Hospital Land Force For Pla
Priority to CN 92100755 priority Critical patent/CN1075081A/en
Publication of CN1075081A publication Critical patent/CN1075081A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to narcotic compound method, particularly a kind of compound method of colloid anaesthetic compound of the mucomembranous surface anesthesia that is applicable to surgical examination or treatment, that existing aqueous solution anesthetis is held time is short, anaesthetic effect difference and toxic reaction easily takes place, and also will use other lubricant simultaneously.The present invention adds hibitane, tetracain hydrochloride, etamsylate, gentamycin sulfate and glycerol, liquid paraffin etc. after carmellose is soaked to be mixed with colloid anaesthetic compound again, this anesthetis is long in the mucomembranous surface time of staying, not only can improve anaesthetic effect, also have hemostasis, antiinflammatory and effect such as lubricated simultaneously, need again with lubricator.

Description

The compound method of colloid anaesthetic compound
The present invention relates to narcotic compound method, particularly a kind of compound method of colloid anaesthetic compound of the mucomembranous surface anesthesia that is applicable to surgical examination or treatment.
Mucomembranous surface anesthesia is the anesthesia that six kinds of surgeries are checked or treatment is commonly used, for example various inspections and the treatment of Urology Surgery; Various splanchnoscopies; Trachea is checked; Clinical catheterization ... or the like various inspections and treatment, all use the aqueous solution of lidocaine hydrochloride or tetracain hydrochloride to carry out mucomembranous surface anesthesia for many years as anesthetis, because this narcotic aqueous solution is shorter in the mucomembranous surface time of staying, absorb fast, make its weak point of holding time, the anesthesia wellability is poor, and toxic reaction easily takes place, and need use other lubricant simultaneously, not too convenient during use.
Above-mentioned variety of issue in view of the prior art existence, the objective of the invention is to: the compound method that a kind of colloid anaesthetic compound is provided, transform aqueous solution anesthetis as glue, make it long in the mucomembranous surface holdup time, good and the length of holding time of anaesthetic effect, improve the mucomembranous surface anesthesia effect, also can reach hemostasis, antiinflammatory and lubricated purpose simultaneously.
Add chlorhexidine hydrochloride, tetracain hydrochloride, gentamycin sulfate, etamsylate, glycerol, liquid paraffin etc. again after the present invention is achieved in that and adopts carmellose to be soaked in water and mix stirring, because wherein the hibitane dissolubility is lower, add mixed solution again after the available warm water dissolving, be distributed into bottle after stirring, with cobalt-60 irradiation or to get final product after the flowing steam sterilization.Its consumption of various medicines that is added during preparation 500mL colloid anaesthetic compound is:
Chlorhexidine hydrochloride 0.1g-0.2g
Tetracain hydrochloride 6g-8g
Etamsylate 2g-4g
Carmellose 10g-15g
Liquid paraffin 7mL-10mL
Glycerol 80mL-50mL
Water adds to 500mL
Gentamycin sulfate 16-32 million international units
Colloid anaesthetic compound according to method preparation of the present invention, aqueous solution anesthetis contrast through acute toxicity and onset time and animal experiment of holding time and 1100 many cases clinic trial quantity same with it shows, has the enhancing anaesthetic effect, prolong analgesic time, also have antiinflammatory, hemostasis, effect such as lubricated simultaneously, do not need other adapted lubricant, be applicable to very much the mucomembranous anesthesia at each position.Animal acute toxicity test selects for use rabbit and white mice to carry out, its test data tabulate in after.
Table one: acute toxicity test
Grouping The survival number Death toll Add up to Ratio (P)
Experimental group 14 6 20 <0.01
Matched group 8 17 20 <0.01
Table two: onset time and hold time the test minute
Project Experimental group Matched group Ratio (P)
Onset time 12 11 >0.05
Hold time 115 69 <0.01
In cystoscopy, overlap the stone art through 1100 many cases clinical practices, dilation of urethra, the bladder electrocautery, the anaesthetic effect statistics of various operations such as urethral catheterization is listed table three in.
Except that the operation of above-mentioned clinical practice, the colloid anaesthetic compound that also has operations such as various splanchnoscopies such as gastroscope bronchial microscope etc. and tracheal intubation all can adopt the present invention to prepare.Prepare the medicine that this anesthetis uses and obtain easily, preparation method is simple, need not special installation; Colloid anaesthetic compound viscosity by method preparation of the present invention is suitable, strong adhesion, the anesthesia wellability is good, compares with aqueous solution anesthetis, toxicity is little, holding time obviously prolongs, and need not to use other lubricant, easy to operate when making its operation, have antiinflammatory, anastalsis simultaneously, do not need reuse antibiotics after the general operation, slight haemolysis is had haemostatic effect preferably, the mucomembranous anesthesia when being applicable to urologic examination treatment and other splanchnoscopy.But this colloid anaesthetic compound long term store is easy to carry, uses significant under field condition.
Embodiment: preparation 500mL colloid anaesthetic compound, prepare various medicines by following prescription:
Chlorhexidine hydrochloride 0.15g
Tetracain hydrochloride 7g
Etamsylate 2g
Carmellose 18g
Liquid paraffin 10mL
Glycerol 40mL
Gentamycin sulfate 16 million international units
Distilled water is an amount of
At first with carmellose with an amount of distilled water immersion 24 hours, and hibitane dissolved with warm water, add its various compositions then one by one, and add water to 500mL and stir, be packed as one bottle of 10mL, with the cobalt-60 illumination-based disinfection colloid anaesthetic compound that gets product.

Claims (3)

1, the compound method of colloid anaesthetic compound is a kind of narcotic compound method that is used for mucomembranous anesthesia, it is characterized in that:
A) take by weighing carmellose by the prescription consumption, be soaked in water 24 hours;
B) take by weighing hibitane by the prescription consumption, add warm water and make its dissolving;
C) add one by one in the carmellose soak with dissolved hibitane and by the ready tetracain hydrochloride of prescription, etamsylate, liquid paraffin, gentamycin sulfate, glycerol etc., adding distil water is to 500ml, and stirring gets final product.
2, according to the described compound method of claim 1, it is characterized in that: the consumption of various compositions is calculated as by preparation 500mL colloid anaesthetic compound:
Chlorhexidine hydrochloride 0.1-0.2g
Tetracain hydrochloride 6-8g
Etamsylate 2-4g
Carmellose 10-15g
Liquid paraffin 80-50mL
Gentamycin sulfate 16-82 million international units
Add water to 500mL
3, according to claim 1 or 2 described compound methods, it is characterized in that: the consumption of the required various compositions of preparation 500mL colloid anaesthetic compound is:
Chlorhexidine hydrochloride 0.15g
Etamsylate 2g
Carmellose 13g
Tetracain hydrochloride 7g
Liquid paraffin 10mL
Glycerol 40mL
Gentamycin sulfate 16 million international units
Add water to 500mL
CN 92100755 1992-02-01 1992-02-01 The compound method of colloid anaesthetic compound Pending CN1075081A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 92100755 CN1075081A (en) 1992-02-01 1992-02-01 The compound method of colloid anaesthetic compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 92100755 CN1075081A (en) 1992-02-01 1992-02-01 The compound method of colloid anaesthetic compound

Publications (1)

Publication Number Publication Date
CN1075081A true CN1075081A (en) 1993-08-11

Family

ID=4938777

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 92100755 Pending CN1075081A (en) 1992-02-01 1992-02-01 The compound method of colloid anaesthetic compound

Country Status (1)

Country Link
CN (1) CN1075081A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006221A1 (en) * 2005-07-12 2007-01-18 Fuchao Li Synergistic time-delaying agent for local anestheic
CN1304052C (en) * 1998-04-21 2007-03-14 帝人株式会社 Medicinal compositions for application to mucosa
CN104352485A (en) * 2014-11-12 2015-02-18 武汉大学 Tetracaine hydrochloride oral cavity anesthetic liquid and preparation method thereof
WO2015024420A1 (en) 2013-08-20 2015-02-26 Li Fuchao Local anesthesia pain-relieving time-delay agent
CN105616478A (en) * 2016-02-03 2016-06-01 卢连伟 Local anesthesia gel preparation and preparation method thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304052C (en) * 1998-04-21 2007-03-14 帝人株式会社 Medicinal compositions for application to mucosa
WO2007006221A1 (en) * 2005-07-12 2007-01-18 Fuchao Li Synergistic time-delaying agent for local anestheic
US7928141B2 (en) * 2005-07-12 2011-04-19 Fuchao Li Synergistic compositions and methods for enhancing potency and/or for prolonging the duration of action of anesthetics
JP4865792B2 (en) * 2005-07-12 2012-02-01 赴朝 李 Local anesthetic effect enhancement / time extender
WO2015024420A1 (en) 2013-08-20 2015-02-26 Li Fuchao Local anesthesia pain-relieving time-delay agent
CN104352485A (en) * 2014-11-12 2015-02-18 武汉大学 Tetracaine hydrochloride oral cavity anesthetic liquid and preparation method thereof
CN105616478A (en) * 2016-02-03 2016-06-01 卢连伟 Local anesthesia gel preparation and preparation method thereof

Similar Documents

Publication Publication Date Title
US8685904B2 (en) Aqueous lubricant emulsion for medical or apparatus and a method of washing
Ludolph et al. Negative pressure wound treatment with computer‐controlled irrigation/instillation decreases bacterial load in contaminated wounds and facilitates wound closure
Ciresi et al. Failure of antiseptic bonding to prevent central venous catheter-related infection and sepsis.
Faught et al. Splenic abscess: presentation, treatment options, and results
BUXTON et al. Contamination of intravenous infusion fluid: effects of changing administration sets
Rosai The nature of myospherulosis of the upper respiratory tract
CN1075081A (en) The compound method of colloid anaesthetic compound
CN104365581A (en) Novel specimen conservation solution
GB2144630A (en) Pharmaceutical composition containing chitosan
Summerhays Treatment of traumatically induced synovial sepsis in horses with gentamicin‐impregnated collagen sponges
Khotimchenko et al. Lead absorption and excretion in rats given insoluble salts of pectin and alginate
AU676473B2 (en) Product and process for treating bovine mastitis and bovine metritis
Inglis New insights into the pathogenesis of ventilator-associated pneumonia
EP0166971A1 (en) Insulin preparations, process for their preparation and their use
Evans et al. Bacterial content of enucleated prostate glands
Tomioka et al. Ultrasound‐Guided Peripheral Nerve Blocks Performed by Orthopedic Surgeons: A Retrospective, Multicenter Study in Akita Prefecture, Japan
Kline et al. STUDIES UPON EXPERIMENTAL PNEUMONIA IN RABBITS: V. The Rôle of the Leucocyte in Experimental Pneumonia. The Relation of the Number of Organisms Injected to the Mortality.
Lindblad et al. Variation in Treatment Outcome According to Center Size
CN1032818C (en) Poly ether type polyurethane and polyurethane bismuth, its preparing method and using as oviducal embolism material
Manncke et al. Benefit and advantage to clinicians of a computer-assisted microbiological diagnosis and database system
Noskova et al. Topicality of creation of ointment with herbal extracts for use in veterinary practice
Elisa et al. A small‐bore wire‐guided chest tube for the initial stabilisation of septic uroperitoneum in a dog
DE735912C (en) Drying agents
Moulvi et al. Efficacy of intramuscular alongwith intra-articular gentamicin in the treatment of infectious arthritis in calves
Rosenbloom Chronic Prostatitis

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication